Pulmonary targeting microparticulate camptothecin delivery system: Anticancer evaluation in a rat orthotopic lung cancer model

Anti-Cancer Drugs

Volumn 21, Issue 1, 2010, Pages 65-76

  Chao, Piyun ^a,c   Deshmukh, Manjeet ^a,b   Kutscher, Hilliard L ^a   Gao, Dayuan ^a   Rajan, Sujata Sundara ^a   Hu, Peidi ^a,d   Laskin, Debra L ^a,b   Stein, Stanley ^a   Sinko, Patrick J ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b Environmental and Occupational Health Sciences Institute   (United States)

^c Hurel Corporation   (United States)

^d Experimental Station   (United States)

Author keywords

Camptothecin; Lung cancer; Microparticles; Passive pulmonary targeting

Indexed keywords

CAMPTOTHECIN; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, INTRAVENOUS; LUNG; LUNG NEOPLASMS; MACROPHAGES; MALE; MAXIMUM TOLERATED DOSE; MICROSCOPY, ELECTRON, SCANNING; NEOPLASM TRANSPLANTATION; PARTICLE SIZE; PHAGOCYTOSIS; POLYSTYRENES; PRODRUGS; RATS; RATS, NUDE; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE PROPERTIES;

EID: 74349091948     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328332a322     Document Type: Article

References (52)

1. Jemal A, Siegel R,Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Travis WD, Lubin J, Ries L, Devesa S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996; 77:2464-2470.
3. Giaccone G, Pinedo HM. Drug resistance. Oncologist 1996; 1:82-87.
4. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5:219-234.
5. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-18.
6. Ferreira CG, Huisman C, Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002; 41:57-77. (Pubitemid 34055730)
7. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545-1552.
8. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall- cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-784. (Pubitemid 41103588)
9. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899.
10. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22:785-794. (Pubitemid 41103589)
11. Cabebe E,Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007; 8:15-27.
12. Brewer J, Dunning J. An in vitro and in vivo study of glass particles in ampules. J Am Pharmacol Assoc 1947; 36:289-293.
13. Kanke M, Simmons GH, Weiss DL, Bivins BA, DeLuca PP. Clearance of 141Ce-labeled microspheres from blood and distribution in specific organs following intravenous and intraarterial administration in beagle dogs. J Pharm Sci 1980; 69:755-762.
14. Prinzmetal M, Ornitz EM Jr, Simkin B, Bergman HC. Arterio-venous anastomoses in liver, spleen, and lungs. Am J Physiol 1947; 152:48-52.
15. Scheffel U, Rhodes BA, Natarajan TK,Wagner HN Jr. Albumin microspheres for study of the reticuloendothelial system. J Nucl Med 1972; 13:498-503.
16. Schroeder HG, Simmons GH, DeLuca PP. Distribution of radiolabeled subvisible microspheres after intravenous administration to beagle dogs. J Pharm Sci 1978; 67:504-507.
17. Niden A, Aviado D. Effects of pulmonary embolism on the pulmonary circulation with special reference to arteriovenous shunts in the lung. Circ Res 1956; 4:67-73.
18. Presson RG Jr, Todoran TM, De Witt BJ, McMurtry IF, Wagner WW Jr. Capillary recruitment and transit time in the rat lung. J Appl Physiol 1997; 83:543-549.
19. Colombetti LG, Moerlien S, Pinsky S. Rapid and reliable preparation of macroaggregated albumin suitable for lung scintigraphy. Int J Nucl Med Biol 1975; 2:180-184.
20. Hapke EJ, Pederson HJ. Ultrastructural changes in rat lungs induced by radioactive macroaggregated albumin. Am Rev Respir Dis 1969; 100:194-205.
21. Stauber RE, Mochizuki T, Van Thiel DH, Tauxe WN. The use of quantitative scintigraphy in the measurement of portal-systemic shunting in rats. Ann Nucl Med 1992; 6:209-214.
22. DeLand FH. The fate of macroaggregated albumin used in lung scanning. J Nucl Med 1966; 7:883-895.
23. McGhee JR, Czerkinsky C, Mestecky J. Mucosal vaccines: overview. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, editors. Mucosal immunology. San Diego, California: Academic Press; 1999. pp. 741-757.
24. Taplin GV, Johnson DE, Kennady JC, Dore EK, Poe ND, Swanson LA, et al. Aggregated albumin labeled with various radioisotopes. In: Andrews GA, Kniseley RM, Wagner HN Jr, editors. Radioactive Pharmaceuticals; Proceedings of a symposium held at the Oak Ridge Institute of Nuclear Studies November 1-4, 1965. Oak Ridge: US Atomic Energy Commission, Division of Technical Information; 1966. pp. 525-551.
25. DeNardo GL, Goodwin DA, Ravasini R, Dietrich PA. The ventilatory lung scan in the diagnosis of pulmonary embolism. N Engl J Med 1970; 282:1334-1336.
26. Udenfriend S, Stein S, Bohlen P, Dairman W, Leimgruber W, Weigele M. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science 1972; 178:871-872.
27. Ahmed F, Vyas V, Saleem A, Li XG, Zamek R, Cornfield A, et al. High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin. J Chromatogr B Biomed Sci Appl 1998; 707:227-233.
28. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B Biomed Sci Appl 1997; 691:161-171.
29. Palumbo M, Sissi C, Gatto B, Moro S, Zagotto G. Quantitation of camptothecin and related compounds. J Chromatogr B Biomed Sci Appl 2001; 764:121-140.
30. Scott DO, Bindra DS, Stella VJ. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats. Pharm Res 1993; 10:1451-1457.
31. Johnston MR, Mullen JB, Pagura ME, Howard RB. Validation of an orthotopic model of human lung cancer with regional and systemic metastases. Ann Thorac Surg 2001; 71:1120-1125.
32. March TH, Marron-Terada PG, Belinsky SA. Refinement of an orthotopic lung cancer model in the nude rat. Vet Pathol 2001; 38:483-490.
33. Howard RB, Chu H, Zeligman BE, Marcell T, Bunn PA, McLemore TL, et al. Irradiated nude rat model for orthotopic human lung cancers. Cancer Res 1991; 51:3274-3280.
34. Cambron H, Latulippe JF, Nguyen T, Cartier R. Orotracheal intubation of rats by transillumination. Lab Anim Sci 1995; 45:303-304.
35. Paranjpe PV, Chen Y, Kholodovych V, Welsh W, Stein S, Sinko PJ. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation. J Control Release 2004; 100: 275-292.
36. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 1991; 14:341-349.
37. Kaneda N, Kurita A, Hosokawa Y, Yokokura T, Awazu S. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats. Cancer Res 1997; 57:5305-5308.
38. Kurita A, Kaneda N. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, prospekt. J Chromatogr B Biomed Sci Appl 1999; 724:335-344.
39. Muller RH, Ruhl D, Luck M, Paulke BR. Influence of fluorescent labelling of polystyrene particles on phagocytic uptake, surface hydrophobicity, and plasma protein adsorption. Pharm Res 1997; 14:18-24.
40. Foster KA, Yazdanian M, Audus KL. Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium. J Pharm Pharmacol 2001; 53:57-66.
41. Thiele L, Rothen-Rutishauser B, Jilek S,Wunderli-Allenspach H, Merkle HP, Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J Control Release 2001; 76:59-71.
42. Cannon GJ, Swanson JA. The macrophage capacity for phagocytosis. J Cell Sci 1992; 101:907-913.
43. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263:1600-1603.
44. Dunn SE, Brindley A, Davis SS, Davies MC, Illum L. Polystyrene-poly (ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution. Pharm Res 1994; 11:1016-1022.
45. Moghimi SM. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim Biophys Acta 2002; 1590:131-139.
46. Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AG, Taylor DC, et al. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res 1994; 11:1800-1808. (Pubitemid 24377094)
47. Ayhan H, Tuncel A, Bor N, Piskin E. Phagocytosis of monosize polystyrenebased microspheres having different size and surface properties. J Biomater Sci Polym Ed 1995; 7:329-342.
48. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nano- and microspheres II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 1998; 46:255-263.
49. Schluep T, Cheng J, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 2006; 57:654-662.
50. Tsai TH, Chen YF, Chou CJ, Chen CF. Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection. J Chromatogr A 2000; 870:221-226.
51. Lalloo AK, Luo FR, Guo A, Paranjpe PV, Lee SH, Vyas V, et al. Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2). BMC Med 2004; 2:16.
52. Torky AR, Stehfest E, Viehweger K, Taege C, Foth H. Immuno-histochemical detection of MRPs in human lung cells in culture. Toxicology 2005; 207:437-450.